PE01462005A1 - Resistant transdermal dosage form to manipulation - Google Patents

Resistant transdermal dosage form to manipulation

Info

Publication number
PE01462005A1
PE01462005A1 PE0004342004A PE0004342004A PE01462005A1 PE 01462005 A1 PE01462005 A1 PE 01462005A1 PE 0004342004 A PE0004342004 A PE 0004342004A PE 0004342004 A PE0004342004 A PE 0004342004A PE 01462005 A1 PE01462005 A1 PE 01462005A1
Authority
PE
Peru
Prior art keywords
adverse
agent
dosage form
active
component
Prior art date
Application number
PE0004342004A
Other languages
Spanish (es)
Inventor
Stephen A Howard
Bruce Reidenberg
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US46723503P priority Critical
Priority to US46724303P priority
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of PE01462005A1 publication Critical patent/PE01462005A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33436723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE01462005(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs

Abstract

SE REFIERE A UNA FORMA DE DOSIFICACION TRANSDERMICA QUE COMPRENDE: a) UN COMPONENTE ACTIVO CON UN MATERIAL POLIMERICO DONDE EL AGENTE ACTIVO SE DISPERSA EN FORMA HOMOGENEA EN DICHO MATERIAL, ADEMAS POSEE UNA SUPERFICIE PROXIMA Y UNA DISTAL; It means a transdermal dosage form comprising: a) an active component with a polymeric material wherein the active agent is dispersed homogeneously in said material, also has a proximal and a distal surface; b) UN AGENTE ADVERSO QUE SE ENCUENTRA UBICADO DISTALMENTE DEL COMPONENTE ACTIVO. b) an agent ADVERSE that is located distally of the active component. LA FORMA DE DOSIFICACION COMPRENDE UNA BARRERA INTERPUESTA ENTRE LA SUPERFICIE DISTAL DEL COMPONENTE ACTIVO Y EL COMPONENTE ADVERSO DONDE LA BARRERA ES IMPERMEABLE AL ESPARCIMIENTO DEL AGENTE ACTIVO Y ADVERSO. THE dosage form comprises an intervening barrier between the distal surface of the active component and the adverse COMPONENT where the barrier is impermeable to active agent BROADCAST AND ADVERSE. TAMBIEN SE REFIERE A UN COMPONENTE ADHESIVO QUE CONECTA AMBOS COMPONENTES; Also it refers to an adhesive component connecting the two components; UNA CAPA PROTECTORA SELECCIONADA DE UNA PELICULA POLIMERICA CONTINUA O SUPERPUESTA DONDE EL AGENTE ADVERSO SE INTERPONE ENTRE LA BARRERA Y LA CAPA PROTECTORA. A CHAPE selected from a polymer film CONTINUING OR ADVERSE SUPERIMPOSED where the agent is interposed between the barrier and the CHAPE. LA FORMA DE DOSIFICACION COMPRENDE UNA PLURALIDAD DE CANALES QUE PASAN ENTRE LAS SUPERFICIES PROXIMAL Y DISTAL DEL COMPONENTE ACTIVO. The dosage form comprises a plurality of channels passing between the proximal and distal surfaces of the active component. EL AGENTE ACTIVO SE SELECCIONA DE UN AGONISTA OPIOIDE TAL COMO ALFENTANIL, ALILPRODINA, CODEINA, METADONA, MORFINA, ENTRE OTROS Y EL AGENTE ADVERSO ES UN ANTAGONISTA OPIOIDE SELECCIONADO DE NALOXONA, NALORFINA, CICLAZACINA, ENTRE OTROS The active agent is selected from an opioid agonist alfentanil AS, allylprodine, codeine, methadone, morphine, AMONG OTHERS AND ADVERSE AGENT IS A SELECTED opioid antagonist naloxone, nalorphine, cyclazacine, AMONG OTHERS
PE0004342004A 2003-04-30 2004-04-30 Resistant transdermal dosage form to manipulation PE01462005A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US46723503P true 2003-04-30 2003-04-30
US46724303P true 2003-04-30 2003-04-30

Publications (1)

Publication Number Publication Date
PE01462005A1 true PE01462005A1 (en) 2005-03-26

Family

ID=33436723

Family Applications (2)

Application Number Title Priority Date Filing Date
PE0004342004A PE01462005A1 (en) 2003-04-30 2004-04-30 Resistant transdermal dosage form to manipulation
PE0008672008A PE12972008A1 (en) 2003-04-30 2004-04-30 Resistant transdermal dosage form to manipulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE0008672008A PE12972008A1 (en) 2003-04-30 2004-04-30 Resistant transdermal dosage form to manipulation

Country Status (22)

Country Link
US (1) US8778382B2 (en)
EP (3) EP2316440A1 (en)
JP (1) JP5048324B2 (en)
KR (1) KR101159828B1 (en)
AR (1) AR047936A1 (en)
AU (1) AU2004235794B8 (en)
BR (1) BRPI0409945A (en)
CA (1) CA2522529C (en)
CL (1) CL2004000927A1 (en)
EA (1) EA009623B1 (en)
EC (1) ECSP056191A (en)
IS (1) IS2935B (en)
ME (1) ME00276B (en)
MX (1) MXPA05011703A (en)
MY (1) MY141815A (en)
NO (1) NO332157B1 (en)
NZ (1) NZ542969A (en)
PE (2) PE01462005A1 (en)
RS (1) RS20050812A (en)
TW (1) TWI350186B (en)
UA (1) UA82880C2 (en)
WO (1) WO2004098567A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
PE01462005A1 (en) 2003-04-30 2005-03-26 Purdue Pharma Lp Resistant transdermal dosage form to manipulation
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
PT2074989E (en) * 2004-02-23 2014-02-06 Euro Celtique Sa Abuse resistance opioid transdermal delivery device
DE102004039570B4 (en) * 2004-08-14 2007-03-01 Lts Lohmann Therapie-Systeme Ag Monitoring system for collecting and transdermal Next diffusion of Umweltkontaminantien containing air and method therefor
EP1796651B1 (en) * 2004-08-20 2015-05-20 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Unbreakable dosage forms with delayed release
TWI419717B (en) * 2005-06-17 2013-12-21 Altea Therapeutics Corp Permeant delivery system and methods for use thereof
JP4704829B2 (en) * 2005-07-15 2011-06-22 ニプロパッチ株式会社 Patch, and patch package body
BRPI0619806A2 (en) * 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc Supply device for transmucosal drug abuse resistant
TW200800223A (en) * 2005-12-21 2008-01-01 Shire Pharmaceuticals Inc Transdermal delivery of meptazinol
EP2061441A2 (en) * 2006-08-14 2009-05-27 Shire Pharmaceuticals, Inc. Transdermal delivery of meptazinol
US7740879B2 (en) * 2006-01-17 2010-06-22 Harrogate Holdings Abuse resistant transdermal drug delivery patch
JP2009528990A (en) * 2006-02-13 2009-08-13 アヴィバ ドラッグ デリバリー システムズ Adhesive preparation containing sufentanil and methods of using the same
CN101454007B (en) 2006-07-14 2011-04-13 久光制药株式会社 Adhesive
CN103550136B (en) 2006-07-21 2016-04-13 生物递送科学国际公司 Transmucosal absorption enhancement of the delivery device
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with impeded abuse
TWI454288B (en) 2008-01-25 2014-10-01 Gruenenthal Chemie Pharmaceutical dosage form
CA2723438C (en) 2008-05-09 2016-10-11 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
AU2009294308B2 (en) * 2008-09-18 2013-05-30 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
TWI541246B (en) 2008-12-08 2016-07-11 Euro Celtique Sa Dihydroetorphine
CA2767888C (en) 2009-07-22 2017-09-12 Gruenenthal Gmbh Tamper-resistant dosage form for oxidation-sensitive opioids
PE10672012A1 (en) 2009-07-22 2012-09-05 Gruenenthal Chemie Form of controlled release dosage extruded by hot melt
CN102821757B (en) 2010-02-03 2016-01-20 格吕伦塔尔有限公司 Preparation of a powdered pharmaceutical composition by an extruder
JP2013523780A (en) * 2010-04-02 2013-06-17 オールトランツ インコーポレイティド Opiate agonists and agonists - abuse deterrent transdermal formulation of the antagonist
CN103002881B (en) 2010-05-10 2015-09-02 欧洲凯尔特公司 Compositions containing the active agent particles and the additional active agent
BR112012028788A2 (en) 2010-05-10 2016-07-19 Euro Celtique Sa manufacturing granules without active
EP2568967B1 (en) 2010-05-10 2018-10-24 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012023030A2 (en) * 2010-08-18 2012-02-23 Purdue Pharma L.P. Vacuum avoiding packaging systems and methods thereof
JP5933553B2 (en) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Abuse-resistant dosage form comprising an anionic polymer
HUE034711T2 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
CA2845634A1 (en) 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN104736176B (en) * 2012-08-24 2017-10-13 英特格拉斯疗法有限公司 For enhancing the chemical compositions and methods for transdermal delivery of therapeutic agents
EP2934497B1 (en) 2012-12-21 2016-11-23 Teikoku Pharma USA, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
WO2014145699A1 (en) * 2013-03-15 2014-09-18 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
JP6445537B2 (en) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Modified anti containing one or more particles (tamper-resistant) dosage forms
EA030310B1 (en) 2013-11-13 2018-07-31 Эро-Селтик С.А. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2937649A1 (en) * 2014-01-22 2015-07-30 4P Therapeutics Abuse and misuse deterrent transdermal systems
JP2017518980A (en) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Containing tapentadol, modified prevent immediate release capsule formulation
MX2016015417A (en) 2014-05-26 2017-02-22 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping.
EP3233081A4 (en) * 2014-12-19 2018-07-04 3M Innovative Properties Company Transdermal drug delivery device including fentanyl
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
KR20170139158A (en) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 Immediately released and prevent the tamper-resistant dosage form extraction solvent
US20190015352A1 (en) * 2017-07-14 2019-01-17 Pendleton Brewster Wickersham Applicators & Patches for Dermal & Transdermal Treatment Material & Drug Delivery, Methods of Making Them, & Methods of Use

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1602344A (en) 1924-01-09 1926-10-05 Eagle Peter Medicating compress
US2807262A (en) 1952-12-10 1957-09-24 Robert B Lew Perforated plastic adhesive tape bandage
US3598122B1 (en) * 1969-04-01 1982-11-23
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951B1 (en) * 1971-08-09 1982-11-23
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4539256A (en) 1982-09-09 1985-09-03 Minnesota Mining And Manufacturing Co. Microporous sheet material, method of making and articles made therewith
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
DE3546830C2 (en) 1984-07-23 1995-07-20 Alza Corp Device for delivering fentanyl across the skin
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4687481A (en) * 1984-10-01 1987-08-18 Biotek, Inc. Transdermal drug delivery system
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4960467A (en) 1985-02-11 1990-10-02 The United States Of America As Represented By The Secretary Of The Army Dermal substance collection device
US5788983A (en) * 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4693776A (en) 1985-05-16 1987-09-15 Minnesota Mining And Manufacturing Company Macromer reinforced pressure sensitive skin adhesive
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4743249A (en) * 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4954343A (en) 1986-03-29 1990-09-04 Nitto Electric Industrial Co., Ltd. Dermal pharmaceutical preparations
DE3634016C2 (en) * 1986-04-17 1992-04-09 Lohmann Gmbh & Co Kg, 5450 Neuwied, De
KR970008118B1 (en) * 1987-07-09 1997-05-21 호프만, 마쓰 Transdermal therapeutic system
US4908027A (en) 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5186939A (en) * 1987-04-23 1993-02-16 Cygnus Therapeutic Systems Laminated composite for transdermal administration of fentanyl
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US4917688A (en) * 1987-01-14 1990-04-17 Nelson Research & Development Co. Bandage for transdermal delivery of systemically-active drug
US4822802A (en) * 1987-02-24 1989-04-18 Alza Corporation Method of fentanly administration for postoperative pain relief
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
JPH0696529B2 (en) 1987-03-31 1994-11-30 日本油脂株式会社 Nitroglycerin patch and method of manufacturing
US4879297A (en) 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
US4788064A (en) 1987-07-31 1988-11-29 Warner-Lambert Company Transdermal delivery system
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
ES2062093T3 (en) * 1988-08-02 1994-12-16 Ciba Geigy Ag Plaster layers.
US5185329A (en) * 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5176917A (en) * 1989-03-15 1993-01-05 Lts Lohmann Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
US5053227A (en) 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4978532A (en) 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5750136A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US5750134A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
SE8904296D0 (en) * 1989-12-21 1989-12-21 Pharmacia Ab transdermal system
US5032637A (en) * 1990-03-14 1991-07-16 Adhesives Research Inc. Water-inactivatable pressure sensitive adhesive
US5149719A (en) 1990-04-27 1992-09-22 Minnesota Mining And Manufacturing Company Composition for transdermal penetration of medicaments
DE4020144C2 (en) * 1990-06-25 1993-07-29 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5382246A (en) * 1990-09-18 1995-01-17 Koyo Disposable Goods Company Disposable diaper
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5981666A (en) 1991-07-12 1999-11-09 Adhesives Research, Inc. Method for the production of a high performance pressure sensitive adhesive
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5352516A (en) 1992-01-31 1994-10-04 Adhesives Research, Inc. Water-inactivatable pressure sensitive adhesive
US5756117A (en) * 1992-04-08 1998-05-26 International Medical Asscociates, Inc. Multidose transdermal drug delivery system
US5264219A (en) 1992-08-07 1993-11-23 Minnesota Mining And Manufacturing Company Transdermal drug delivery backing
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5462743A (en) * 1992-10-30 1995-10-31 Medipro Sciences Limited Substance transfer system for topical application
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
JP3592715B2 (en) 1993-10-29 2004-11-24 ミネソタ マイニング アンド マニュファクチャリング カンパニー Pressure sensitive adhesive having a microstructured surface
US5508367A (en) 1993-11-29 1996-04-16 Adhesives Research, Inc. Water-soluble pressure sensitive adhesive
US5395907A (en) * 1993-11-29 1995-03-07 Adhesive Research, Inc. Water-soluble pressure sensitive adhesive
US5494680A (en) 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
JPH07206710A (en) 1994-01-21 1995-08-08 Nitto Denko Corp Tape preparation for transcutaneous administration
US5536263A (en) * 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
GB9409281D0 (en) * 1994-05-10 1994-06-29 Svedman Paul Transdermal device
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US5589480A (en) 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
JP3908795B2 (en) * 1994-11-29 2007-04-25 久光製薬株式会社 Ketotifen containing transdermal dosage formulation
US6063838A (en) * 1995-02-16 2000-05-16 3M Innovative Properties Company Blended pressure-sensitive adhesives
US5573778A (en) 1995-03-17 1996-11-12 Adhesives Research, Inc. Drug flux enhancer-tolerant pressure sensitive adhesive composition
US5866143A (en) * 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US6093419A (en) * 1995-06-07 2000-07-25 Lectec Corporation Compliance verification method and device in compulsory drug administration
AU6657396A (en) * 1995-07-28 1997-02-26 Novartis Ag Transdermal system
US5840327A (en) * 1995-08-21 1998-11-24 Alza Corporation Transdermal drug delivery device having enhanced adhesion
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
US5703169A (en) 1996-01-24 1997-12-30 Adhesives Research, Inc. Non-corrosive, low volatiles-containing pressure sensitive adhesive
AU2059297A (en) * 1996-03-12 1997-10-01 Alza Corporation Composition and dosage form comprising opioid antagonist
ES2177962T3 (en) 1996-03-25 2002-12-16 Lohmann Therapie Syst Lts Transdermal therapeutic system for application of reduced thickness and high flexibility, and manufacturing process thereof.
US5783583A (en) * 1996-04-12 1998-07-21 Simon; David Lew 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt for the purpose of rapid narcotic detoxification
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
US6271240B1 (en) * 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US6365178B1 (en) * 1996-09-06 2002-04-02 Watson Pharmaceuticals, Inc. Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
DK0934078T3 (en) 1996-10-24 2003-04-14 Alza Corp Permeation enhancers for transdermal administration of active substances, devices and method for preparation thereof
WO1998018416A1 (en) * 1996-10-30 1998-05-07 Theratech, Inc. Fatty acid esters of glycolic acid and its salts as permeation enhancers
DE19653605C2 (en) * 1996-12-20 2002-11-28 Roehm Gmbh Adhesive and binder for dermal or transdermal therapy systems, and its use for the production of a transdermal therapeutic system
DE19653606A1 (en) 1996-12-20 1998-06-25 Roehm Gmbh Adhesive and binder of (meth) acrylate polymer, organic acid and plasticizer
DE19654468C1 (en) 1996-12-27 1998-01-22 Lohmann Therapie Syst Lts Flexible dermal or transdermal plaster for drug or cosmetic release
US6239228B1 (en) * 1997-02-21 2001-05-29 Adhesives Research, Inc. Pressure sensitive adhesive containing macromer having repeat hydrophilic moieties
US5951999A (en) * 1997-02-21 1999-09-14 Adhesives Research, Inc. Transdermal pressure sensitive adhesive drug delivery system
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6132760A (en) 1997-02-28 2000-10-17 3M Innovative Properties Company Transdermal device for the delivery of testosterone
US6018092A (en) * 1997-03-04 2000-01-25 3M Innovative Properties Company Medical adhesive bandage, delivery system and method
US5804215A (en) 1997-03-21 1998-09-08 L. Perrigo Company Transdermal patch disposal system and method
US5976547A (en) 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
US6420622B1 (en) * 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
IT1294748B1 (en) * 1997-09-17 1999-04-12 Permatec Tech Ag A formulation for a transdermal device
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
DK1041987T3 (en) * 1997-12-22 2006-08-21 Euro Celtique Sa An oral pharmaceutical dosage form comprising a combination of an opioid agonist and naltrexone
CA2314896C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6143278A (en) 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6193996B1 (en) * 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
US6294038B1 (en) * 1998-08-05 2001-09-25 Advanced Label Systems, Inc. Apparatus and method for applying linerless labels
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6129929A (en) 1998-10-30 2000-10-10 Noven Pharmaceuticals, Inc. Patch applicator
US6159497A (en) 1998-10-30 2000-12-12 Noven Pharmaceuticals, Inc. Patch applicator
US6136807A (en) 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
US6348210B1 (en) * 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6183770B1 (en) * 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
IL151057D0 (en) * 2000-02-08 2003-04-10 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US20020119187A1 (en) 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
WO2002054996A2 (en) 2000-10-23 2002-07-18 Mark Alfonso Terazosin transdermal device and methods
EP1335689B1 (en) * 2000-10-23 2010-03-17 Euro-Celtique S.A. Loratadine transdermal administration system and use thereof
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
DE02715112T1 (en) 2001-03-16 2007-04-19 Alza Corp., Mountain View Transdermal plaster for administration of fentanyl
ES2342156T3 (en) * 2001-04-23 2010-07-02 Euro-Celtique S.A. Lighting system for transdermal dosage form.
WO2002087482A1 (en) * 2001-05-01 2002-11-07 Euro-Celtique Abuse resistant opioid containing transdermal systems
CA2446550C (en) * 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
AU2002303718B2 (en) * 2001-05-11 2008-02-28 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
DK1390866T3 (en) * 2001-05-22 2010-05-10 Euro Celtique Sa The container and method for dispensing transdermal dosage forms
AU2002313628A1 (en) 2001-05-22 2002-12-03 Euro-Celtique Tamper resistant oral dosage form
US20030064122A1 (en) * 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
EP1414451B1 (en) 2001-08-06 2009-05-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US6893655B2 (en) * 2001-10-09 2005-05-17 3M Innovative Properties Co. Transdermal delivery devices
EP1448456B1 (en) * 2001-10-22 2007-06-13 3M Innovative Properties Company Transdermal/transmucosal patch packaging
AU2002361709A1 (en) * 2001-12-17 2003-06-30 Aryx Therapeutics Analgesic delivery systems and methods of use
US6838078B2 (en) * 2002-01-16 2005-01-04 3M Innovative Properties Company Film-forming compositions and methods
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
RU2209062C1 (en) 2002-03-19 2003-07-27 Институт физиологии им. И.П.Павлова РАН Substance of sedative action
DE60320770D1 (en) 2002-03-20 2008-06-19 Euro Celtique Sa Process for the administration of buprenorphine for treatment of depression
AR039336A1 (en) * 2002-04-23 2005-02-16 Alza Corp transdermal analgesic systems with reduced potential for abuse
PT1513532E (en) * 2002-06-10 2007-05-31 Euro Celtique Sa Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
US20050191340A1 (en) 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
PT1530469E (en) * 2002-08-20 2009-05-19 Euro Celtique Sa Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
US20040043171A1 (en) * 2002-08-30 2004-03-04 Audett Jay Douglas Multilaminate backing construction
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
AT400258T (en) * 2002-12-13 2008-07-15 Euro Celtique Sa Transdermal buprenorphine dosage regimen for the purpose of pain relief
AU2003297074A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
US20040202708A1 (en) 2003-04-14 2004-10-14 3M Innovative Properties Company Transdermal drug delivery device with translucent inorganic barrier layer
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
PE01462005A1 (en) 2003-04-30 2005-03-26 Purdue Pharma Lp Resistant transdermal dosage form to manipulation
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20040219198A1 (en) 2003-05-01 2004-11-04 3M Innovative Properties Company Transdermal drug delivery device with multilayer backing

Also Published As

Publication number Publication date
AR047936A1 (en) 2006-03-15
NO20054682D0 (en) 2005-10-12
PE12972008A1 (en) 2008-09-17
AU2004235794B2 (en) 2009-06-04
KR20070088823A (en) 2007-08-30
RS20050812A (en) 2007-12-31
CL2004000927A1 (en) 2005-01-28
JP2006525370A (en) 2006-11-09
ECSP056191A (en) 2006-04-19
US8778382B2 (en) 2014-07-15
CA2522529C (en) 2015-10-20
MXPA05011703A (en) 2006-01-23
WO2004098567A3 (en) 2005-01-13
EP1641441B1 (en) 2014-03-12
AU2004235794B8 (en) 2009-07-23
NZ542969A (en) 2009-09-25
KR101159828B1 (en) 2012-07-04
US20050002997A1 (en) 2005-01-06
NO20054682A (en) 2005-11-30
IS8060A (en) 2005-10-04
ME00276B (en) 2011-05-10
WO2004098567A2 (en) 2004-11-18
CA2522529A1 (en) 2004-11-18
UA82880C2 (en) 2008-05-26
TW200505509A (en) 2005-02-16
NO332157B1 (en) 2012-07-09
JP5048324B2 (en) 2012-10-17
EP2316440A1 (en) 2011-05-04
AU2004235794A1 (en) 2004-11-18
MEP49208A (en) 2011-02-10
MY141815A (en) 2010-06-30
BRPI0409945A (en) 2006-04-25
IS2935B (en) 2016-01-15
EA009623B1 (en) 2008-02-28
EA200501702A1 (en) 2006-04-28
EP2319505A1 (en) 2011-05-11
TWI350186B (en) 2011-10-11
EP1641441A2 (en) 2006-04-05

Similar Documents

Publication Publication Date Title
RU2428985C2 (en) Drug form containing oxycodon and naloxon
TWI469806B (en) Syringe devices and methods for mixing and administering medication
TW522023B (en) Tablet with controlled release of alfuzosin hydrochloride
AR047112A1 (en) Adn stabilized compositions for coating microprojections
NZ509928A (en) Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
IS7142A (en) Pharmaceutical compositions containing morphine agonist, along with the releasable antagonist hömdu
WO2006031398A3 (en) Compositions containing fast-leaching plasticizers for improved performance of medical devices
ECSP077401A (en) Medicines containing carbonyl compounds and their use
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
WO2008083174A3 (en) Compositions and methods for the treatment of infections and tumors
IL172679A (en) Use of an antibody that blocks an inhibitory receptor or stimulates an activating receptor of an nk cell for the preparation of medicaments, for use in combination with a therapeutic antibody, in the treatment of a disease, pharmaceutical compositions comprising said antibodies and methods to identify said antibodies
NZ556095A (en) Fixed dosing of her antibodies
IL158831A (en) Uses of anti-tnfalpha antibodies in the manufacture of medicaments adapted for subcutaneous biweekly administration, kits comprising them and preloaded syringes comprising them
TWI636809B (en) Drug delivery device and method of manufacturing the drug delivery device
BRPI0510170B1 (en) compound, pharmaceutical composition for the treatment of diseases mediated by muscarinic acetylcholine receptor and the use of the compound
MX2007000610A (en) Combination treatment for non-hematologic malignancies using an anti-ogf-1r antibody.
CA2548915A1 (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
WO2006071274A3 (en) Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
EA200600820A1 (en) Methods of treatment, modifications and elimination of pain using 1-oxo-2- (2,6-dioxopiperidin-3-yl) -4-methylisoindoline
EP2248519A3 (en) Non-mucoadhesive film dosage forms
WO2007028167A3 (en) Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs and uses thereof
CL2004001602A1 (en) Nonsteroidal compounds propionanilide derivatives, androgen receptor modulators with tissue selectivity (SARM); pharmaceutical composition; and use in the treatment or prevention of androgen receptor dependent conditions, such as hi
PE05232006A1 (en) oral dosage forms with controlled release opioid
PE11842009A1 (en) Pharmaceutical dosage forms
SK286888B6 (en) Analgesic composition comprising buprenorphine

Legal Events

Date Code Title Description
FG Grant, registration
AE Restoration of lapsed or forfeited application
FG Grant, registration
FD Application declared void or lapsed